Physician profile
Natalie Mccarty
NPI 1679042733
$2,090.69
in general payments reported to CMS, 2019-2025
38 companies · $26.10 in 2025
The $26.10 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $591 · 2023: $1,282 · 2024: $69.76 · 2025: $26.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.90 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $145.08 | 2023-2025 | |
| Glaxosmithkline, LLC. | $141.02 | 2021-2023 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $132.18 | 2022-2023 | Keytruda, Lynparza |
| Incyte Corporation | $126.65 | 2022-2023 | Jakafi |
| Seagen INC. | $125.97 | 2022-2023 | Tukysa |
| Ipsen Biopharmaceuticals, INC | $119.15 | 2022-2023 | Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $113.78 | 2022-2023 | Fruzaqla |
| Pfizer INC. | $113.61 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $104.22 | 2022-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $87.57 | 2023 | Calquence, Tagrisso, Enhertu |
| Gilead Sciences, INC. | $87.20 | 2022-2023 | Trodelvy |
| Genzyme Corporation | $85.53 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $72.09 | 2022-2023 | Libtayo |
| Genentech USA, INC. | $57.65 | 2023 | Tecentriq, Polivy, Lunsumio |
| Alexion Pharmaceuticals, INC. | $47.71 | 2023 | Ultomiris |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $43.35 | 2023 | |
| Daiichi Sankyo INC. | $41.97 | 2023 | Enhertu |
| Stemline Therapeutics INC. | $35.63 | 2023 | Orserdu |
| Karyopharm Therapeutics INC. | $35.47 | 2023 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.78 | 2023 | Gilotrif |
| Amgen INC. | $33.25 | 2023 | Blincyto, Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $29.24 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $25.10 | 2023 | Avastin |
| G1 Therapeutics, INC. | $23.45 | 2023 | Cosela |
| Alnylam Pharmaceuticals INC. | $23.30 | 2022 | |
| Exelixis INC. | $20.73 | 2023 | Cabometyx |
| Eisai INC. | $20.35 | 2022 | |
| Janssen Biotech, INC. | $19.48 | 2023 | Tecvayli |
| Lilly USA, LLC | $19.06 | 2023 | Jaypirca, Verzenio |
| Celgene Corporation | $15.56 | 2022 | |
| Sumitomo Pharma America, INC. | $15.56 | 2023 | Orgovyx |
| Abbvie INC. | $15.33 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.77 | 2023 | Opdivo |
| Tersera Therapeutics LLC | $13.53 | 2023 | Zoladex |
| Myovant Sciences INC. | $13.22 | 2022 | |
| Servier Pharmaceuticals LLC | $13.19 | 2023 | |
| Foundation Medicine, INC. | $13.17 | 2022 | |
| Adc Therapeutics America, INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.